Thomas John

29.0k total citations · 3 hit papers
260 papers, 6.0k citations indexed

About

Thomas John is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Thomas John has authored 260 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Pulmonary and Respiratory Medicine, 142 papers in Oncology and 52 papers in Cancer Research. Recurrent topics in Thomas John's work include Lung Cancer Treatments and Mutations (114 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (49 papers). Thomas John is often cited by papers focused on Lung Cancer Treatments and Mutations (114 papers), Cancer Immunotherapy and Biomarkers (52 papers) and Lung Cancer Research Studies (49 papers). Thomas John collaborates with scholars based in Australia, United States and Japan. Thomas John's co-authors include Ming‐Sound Tsao, Frances A. Shepherd, Alexander Dobrovic, Puey Ling Chia, Geoffrey Liu, Suresh S. Ramalingam, Paul Mitchell, Yi‐Long Wu, Myung‐Ju Ahn and Yuri Rukazenkov and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Thomas John

248 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations James Chih‐Hsin Yang, Chee Khoon Lee et al. Journal of Clinical Oncology profile →
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

2023 263 citations Roy S. Herbst, Thomas John et al. profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations Yi‐Long Wu, Myung‐Ju Ahn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas John Australia	39	3.7k	3.2k	1.7k	1.1k	535	260	6.0k
Stefan Duensing Germany	46	1.9k 0.5×	2.5k 0.8×	3.6k 2.2×	1.3k 1.2×	687 1.3×	168	7.6k
Francis P. Worden United States	49	2.3k 0.6×	3.5k 1.1×	1.7k 1.0×	1.4k 1.3×	504 0.9×	257	9.1k
Sandra P. D’Angelo United States	37	3.5k 0.9×	5.9k 1.9×	1.2k 0.7×	584 0.5×	1.4k 2.7×	191	7.8k
Samra Turajlic United Kingdom	30	1.4k 0.4×	2.4k 0.8×	2.3k 1.4×	1.3k 1.2×	821 1.5×	98	4.9k
Martijn P. Lolkema Netherlands	44	1.8k 0.5×	4.0k 1.3×	2.9k 1.7×	2.1k 1.9×	1.8k 3.4×	188	8.2k
Andreas Erbersdobler Germany	50	4.3k 1.2×	1.3k 0.4×	2.2k 1.3×	1.8k 1.7×	260 0.5×	226	7.6k
A. Dimitrios Colevas United States	51	2.1k 0.6×	3.4k 1.1×	1.6k 1.0×	582 0.5×	619 1.2×	197	7.6k
Michelle S. Hirsch United States	45	2.3k 0.6×	1.7k 0.5×	2.5k 1.5×	1.3k 1.2×	550 1.0×	194	7.5k
Pier Francesco Ferrucci Italy	37	857 0.2×	3.7k 1.2×	2.9k 1.8×	409 0.4×	1.7k 3.1×	141	6.2k
Christian H. Ottensmeier United Kingdom	51	1.2k 0.3×	3.6k 1.1×	2.4k 1.5×	689 0.6×	3.5k 6.6×	223	8.2k

Countries citing papers authored by Thomas John

Since Specialization

Citations

This map shows the geographic impact of Thomas John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas John more than expected).

Fields of papers citing papers by Thomas John

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas John. The network helps show where Thomas John may publish in the future.

Co-authorship network of co-authors of Thomas John

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas John. A scholar is included among the top collaborators of Thomas John based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas John. Thomas John is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Edbrooke, Lara, Thomas Davies, Catherine L. Granger, et al.. (2025). Development of a clinical core outcome set to evaluate lung cancer rehabilitation. ERJ Open Research. 11(5). 58–2025. 1 indexed citations

Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505. 12 indexed citations

Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2024). Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.. Journal of Clinical Oncology. 42(16_suppl). 8560–8560. 6 indexed citations

John, Thomas, Christian Grohé, Jonathan W. Goldman, et al.. (2024). Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8005–8005. 15 indexed citations

Alexander, Michael J., Michael Faltys, Lydia Warburton, et al.. (2023). 538P First-line chemoimmunotherapy for metastatic thymic carcinoma. Annals of Oncology. 34. S1679–S1680.

Lipworth, Wendy, et al.. (2023). Therapeutic misunderstandings in modern research. Bioethics. 38(2). 138–152. 1 indexed citations

Edbrooke, Lara, Catherine L. Granger, Jill Francis, et al.. (2023). Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set. BMJ Open Respiratory Research. 10(1). e001571–e001571. 8 indexed citations

Woodford, Rachel, Sarah J. Lord, Ian C. Marschner, et al.. (2022). PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology. 18(14). 1793–1799. 8 indexed citations

Murali, Krithika, Tanya Dwarte, Mehrdad Nikfarjam, et al.. (2021). Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. Hereditary Cancer in Clinical Practice. 19(1). 33–33. 5 indexed citations

10.

Anderson, Mark G., Hugh D. Falls, Michael J. Mitten, et al.. (2020). Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate. Molecular Cancer Therapeutics. 19(10). 2117–2125. 30 indexed citations

11.

Lee, Erinna F., Tiffany J. Harris, Sharon Tran, et al.. (2019). BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease. 10(5). 342–342. 142 indexed citations

12.

Li, Na, Simone McInerny, Magnus Zethoven, et al.. (2019). Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. JNCI Journal of the National Cancer Institute. 111(12). 1332–1338. 23 indexed citations

13.

Yanes, Tatiane, Bettina Meiser, Rajneesh Kaur, et al.. (2018). Polygenic breast cancer risk: A prospective study of uptake and outcomes among high-risk women. Twin Research and Human Genetics. 1 indexed citations

14.

Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31). 3591–3600. 77 indexed citations

15.

Wu, Licun, Ghassan Allo, Thomas John, et al.. (2016). Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. Clinical Cancer Research. 23(4). 1060–1067. 40 indexed citations

16.

Parisot, John P., Heather Thorne, Andrew Fellowes, et al.. (2015). “Cancer 2015”: A Prospective, Population-Based Cancer Cohort—Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine. 5(4). 354–369. 8 indexed citations

17.

John, Thomas, Michael A. Black, Tumi Toro, et al.. (2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clinical Cancer Research. 14(16). 5173–5180. 44 indexed citations

18.

Tahhan, Nina, A. Demir, Thomas John, et al.. (2004). Comfort and vision with inverted soft contact lenses. Investigative Ophthalmology & Visual Science. 45(13). 1536–1536. 1 indexed citations

19.

John, Thomas, et al.. (2002). Ultrastructural Findings Of New free-standing, Low-heat Dehydrated Human Amniotic Membrane. Investigative Ophthalmology & Visual Science. 43(13). 4191–4191. 2 indexed citations

20.

John, Thomas, et al.. (1978). Prostate carcinoma: immunostaging and adjuvant immunotherapy with BCG.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 355–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact